Immune-checkpoint inhibitors (ICI) now represent the standard of care for several cancer
types. In pre-clinical models, absence of an intact gut microbiome negatively impacted ICI …

Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role
in oncogenesis and influences response to immune checkpoint blockade (ICB). The …

Background With the advent of immunotherapy, substantial progress has been made in
improving outcomes for patients with advanced cancer. However, not all patients benefit …

Background: The gut microbiota has been shown to be an important determinant of the
efficacy of immune checkpoint inhibitions (ICI) in cancer. Several lines of evidence suggest …

Objectives Gut microbiome plays a dominant role in modulating therapeutic efficacy of
immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor/ligand-1 …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

The gut microbiota plays a critical role in the anti-tumor immune response. There is
increasing data showing that antibiotics (ATBs) change the composition of the gut microbiota …

Background Gut microbial diversity is associated with improved response to immune
checkpoint inhibitors (ICI). Based on the known detrimental impact that antibiotics have on …

Background The use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the
composition and diversity of the gut microbiota, which can influence the immune system …

Tumor immunity consists of various types of cells, which serve an important role in antitumor
therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the …